Sustained virologic response correlated with reduced hepatic venous pressure gradient in patients with HCV-associated cirrhosis, according to a recently published study. However, clinically significant portal hypertension continued to persist in most patients. “Development of [clinically significant portal hypertension] is a hallmark in the natural history of cirrhosis because it is associated with a higher risk of hepatic decompensation, and increased ri
ORLANDO — Measuring hepatic pressure should be done by gastroenterologists and hepatologists because it can best direct treatment and outcomes, according to an international expert at the World Congress of Gastroenterology at ACG 2017. “Liver pressure has come of age. Gastroenterologists and hepatologists besides endoscopy should learn to measure pressures, should use it in routine practice like blood pressure measurements,” Shiv Kumar Sarin, MD, DM, dire
Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad). Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...
Elevated hepatitis B virus core-related antigen levels significantly increased the risk for progression to cirrhosis among patients with chronic hepatitis B who are hepatitis B e antigen-negative and are not receiving nucleos(t)ide analogue therapy, according to recently published data. “Recently, various indices of liver fibrosis based on clinical and biological data have been reported to be useful predictors of fibrosis in liver disease,” Toshifumi Tada
Friday, August 11, 2017 Research & Discoveries Melbourne scientists are creating mini-livers in a dish MELBOURNE scientists are creating mini livers in a dish using a world-first combination of human cells in an ambitious bid to grow liver tissue for transplants. The tiny experimental organs – developed from cells donated by cancer patients – will be used to test drugs and eventually treat disease. Routine hospital tool found to predict poor ...
For patients with chronic hepatitis B (CHB), achievement of subcirrhotic range of liver stiffness (sc-LS) with antiviral therapy (AVT) is associated with reduced risk of hepatocellular carcinoma (HCC), according to a study published in the Journal of Gastroenterology and Hepatology. During the study period, the researchers found that after 2 years of AVT, 67.0% of patients achieved sc-LS and 13.4% of patients developed HCC. "The achievement of sc-LS af
The past decade has seen a nearly 40 percent increase in the prevalence of cirrhosis among people with hepatitis C in the U.S., a new study found. The reasons remain uncertain, however. The study, titled “Hepatitis C Complications: Prevalence and Disparities in a Large US Cohort 2006-2014” (abstract #180) was presented at The Liver Meeting 2016, held by the American Association for the Study of Liver Diseases (AASLD). Cirrhosis has long been linked t
Complications of advanced liver disease including cirrhosis and hepatic decompensation have risen over the past decade among people with chronic hepatitis C, according to study findings presented at the 2016 AASLD Liver Meeting in November. However, in recent years the increase has slowed, especially among those at highest risk – black people and people aged 60 and over. Men had significantly higher decompensation prevalence than women, though both rose a
BOSTON, Nov. 11, 2016 /PRNewswire/ -- Over the past decade, the prevalence of cirrhosis has increased by almost 40 percent among people with hepatitis C (HCV) in the United States, according to research presented at The Liver Meeting® — held by the American Association for the Study of Liver Diseases. Hepatitis C has been linked to cirrhosis (i.e., scarring of the liver), decompensated cirrhosis, and death, but the extent of the prevalence of thes...
Advancing Liver Disease It’s far better for the public health to test broadly for HCV, and to treat it early. Advanced HCV liver disease is costly, painful, and preventable! Left undiagnosed and/or untreated, hepatitis C advances – often silently – until suddenly it is too late. Overview of HCV Disease Progression If acute hepatitis C infection (HCV) becomes a chronic infection it can eventually progress to a more serious disease. Over time it can pro